Eculizumab | Aplastic Anemia & MDS International Foundation Return to top.
  1. Treatments
  2. Drugs
  3. Eculizumab

Eculizumab

Brand name: 
Soliris
Bone Marrow Disease(s): 
  • paroxysmal nocturnal hemoglobinuria (PNH)

Eculizumab causes the complement system, a part of your immune system, to be less active. By doing this it reduces hemolysis, the destruction of red blood cells, in patients with PNH. It is in a class of drugs call monoclonal antibodies.

Related Clinical Trials

Clinical Trial Status Age Group
A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. (COMMODORE 1) Recruiting 12 years and older
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Recruiting
PEGASUS: A Phase III Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH Active, not recruiting 18 years and older
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (APPLY-PNH) Not yet recruiting 18 years and older

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Share with addtoany.com.